pembrolizumab
Powerful new data for MSD’s bladder cancer drug stops trial early
November 16, 2016Research and Development MSD, pembrolizumab
MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …
OncoMed initiates Phase Ib immuno-oncology combination clinical trial
March 18, 2016Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer
January 13, 2016Research and Development MSD, immunotherapy, keytruda, pembrolizumab
Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …
MSD’s Keytruda impresses in lung cancer chemotherapy trial
December 21, 2015Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab
MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
MSD’s Keytruda shows promise in multiple myeloma
December 7, 2015Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab
MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …
Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Merck to test Keytruda combinations
May 8, 2015Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
Merck seeks new Keytruda indication in US
April 20, 2015Sales and Marketing Cancer, FDA, NSCLC, PD-L1, US, keytruda, lung, pembrolizumab
Merck is seeking FDA approval for its successful melanoma drug Keytruda to be used treating lung cancer. The Supplemental Biologics …
Merck lines up early-stage Keytruda combo trial
April 1, 2015Research and Development, Sales and Marketing Cancer, Merck, entinostat, keytruda, pd1, pembrolizumab, syndax
Merck is planning for Keytruda’s future by launching early-stage trials of the drug in combination with an investigational treatment from …
Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival
March 25, 2015Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab
A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …
Merck’s cancer drug sees first ever early access nod
March 11, 2015Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab
Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …
Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
Latest content
FibroFind appoints Lee Borthwick as CEO
